Erosive Esophagitis (DBCOND0032951)

Identifiers

Synonyms

Erosive oesophagitis / Erosive Esophagitis (EE) / Erosive esophagitis / Erosive esophagitis (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Dexlansoprazole	A proton pump inhibitor used to treat erosive esophagitis, heartburn, and gastroesophageal reflux disease (GERD).	Potassium-transporting ATPase alpha chain 1target Cytochrome P450 2C19enzyme Cytochrome P450 3A4enzyme Potassium-transporting ATPase subunit betatarget N(G),N(G)-dimethylarginine dimethylaminohydrolase 1target
Domperidone	A dopamine receptor antagonist used as a peristaltic stimulant and anti-emetic agent for dyspepsia, indigestion, epigastric pain, nausea, and vomiting.	D(2) dopamine receptortarget Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme ATP-dependent translocase ABCB1transporter Cytochrome P450 1A2enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2D6enzyme D(3) dopamine receptortarget
Esomeprazole	A proton pump inhibitor used to treat GERD, reduce the risk of NSAID associated gastric ulcers, eradicate H. pylori, and to treat conditions causing gastric acid hypersecretion.	Potassium-transporting ATPase alpha chain 1target Cytochrome P450 2C19enzyme Cytochrome P450 3A4enzyme N(G),N(G)-dimethylarginine dimethylaminohydrolase 1target ATP-dependent translocase ABCB1transporter Organic anion transporter 3transporter Potassium-transporting ATPase subunit betatarget
Famotidine	A histamine H2 receptor antagonist used to treat duodenal ulcers, benign gastric ulcers, GERD, and Zollinger-Ellison syndrome.	Histamine H2 receptortarget Solute carrier family 22 member 2transporter Organic anion transporter 3transporter Multidrug and toxin extrusion protein 1transporter Cytochrome P450 1A2enzyme Solute carrier family 22 member 6transporter
Lansoprazole	A proton pump inhibitor used to help gastrointestinal ulcers heal, to treat symptoms of gastroesophageal reflux disease (GERD), to eradicate Helicobacter pylori, and to treat hypersecretory conditions such as Zollinger-Ellison Syndrome.	Potassium-transporting ATPase alpha chain 1target Cytochrome P450 2C19enzyme Cytochrome P450 2C9enzyme Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 1A1enzyme Cytochrome P450 1B1enzyme Cytochrome P450 2C18enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2D6enzyme Microtubule-associated protein tautarget Organic anion transporter 3transporter Solute carrier family 22 member 1transporter Solute carrier family 22 member 2transporter Solute carrier family 22 member 3transporter
Omeprazole	A proton pump inhibitor used to treat GERD associated conditions such as heartburn and gastric acid hypersecretion, and to promote healing of tissue damage and ulcers caused by gastric acid and H. pylori infection.	Potassium-transporting ATPase alpha chain 1target Cytochrome P450 2C19enzyme Cytochrome P450 3A4enzyme Cytochrome P450 2C9enzyme Cytochrome P450 1A2enzyme ATP-binding cassette sub-family C member 3transporter ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 1A1enzyme Cytochrome P450 1B1enzyme Cytochrome P450 2C18enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2D6enzyme Aryl hydrocarbon receptortarget Potassium-transporting ATPase subunit betatarget
Pantoprazole	A proton pump inhibitor used to treat erosive esophagitis, gastric acid hypersecretion, and to promote healing of tissue damage caused by gastric acid.	Potassium-transporting ATPase alpha chain 1target Cytochrome P450 2C19enzyme Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Organic anion transporter 3transporter N(G),N(G)-dimethylarginine dimethylaminohydrolase 1target Potassium-transporting ATPase subunit betatarget
Ranitidine	A histamine H2 antagonist used to treat duodenal ulcers, Zollinger-Ellison syndrome, gastric ulcers, GERD, and erosive esophagitis.	Histamine H2 receptortarget Cytochrome P450 1A2enzyme Cytochrome P450 2D6enzyme Solute carrier family 22 member 1transporter ATP-dependent translocase ABCB1transporter Organic anion transporter 3transporter Cytochrome P450 3A4enzyme Acetylcholinesterasetarget Solute carrier family 22 member 2transporter Acetylcholinesteraseenzyme
Vonoprazan	A potassium-competitive acid blocker used in the treatment of acid-related disorders and as an adjunct to Helicobacter pylori eradication.	Hydrogen potassium ATPasetarget Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2D6enzyme ATP-dependent translocase ABCB1transporter Albumincarrier Alpha-1-acid glycoprotein 1carrier

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03615677	Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis	Esomeprazole Tegoprazan	treatment	3	completed
NCT02141711	TAK-438 - Safety, Blood Levels & Effects of Repeated Doses	Vonoprazan	basic_science	1	completed
NCT06391177	A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily	Vonoprazan	basic_science	1	completed
NCT00641602	A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis	Esomeprazole Lansoprazole	treatment	4	completed
NCT02615184	A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children	Dexlansoprazole	treatment	2	recruiting
NCT01509261	Efficacy Study of Ilaprazole to Treat Erosive Esophgitis	Ilaprazole Lansoprazole	treatment	3	completed
NCT05055128	A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole	Lansoprazole	treatment	2	completed
NCT04255693	Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence	No drug interventions	other	Not Available	recruiting
NCT03228407	Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)	No drug interventions	diagnostic	Not Available	unknown_status
NCT05587309	A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis	No drug interventions	treatment	3	recruiting
NCT02388737	Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis	Lansoprazole Vonoprazan	treatment	3	completed
NCT05267613	Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.	Esomeprazole	treatment	3	recruiting
NCT02456935	Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis	Esomeprazole Tegoprazan	treatment	3	completed
NCT00644735	Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed	Esomeprazole Lansoprazole	treatment	4	completed
NCT02028663	Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis	Esomeprazole Tegoprazan	treatment	2	completed
NCT00693225	Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study	Omeprazole Sodium bicarbonate	treatment	4	completed
NCT01452776	Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis	Vonoprazan	treatment	3	completed
NCT03943992	Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)	Esomeprazole	treatment	3	completed
NCT05890001	A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease	No drug interventions	treatment	3	enrolling_by_invitation
NCT01499368	A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients	Famotidine Lafutidine Omeprazole	treatment	3	completed
NCT01630746	A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis	Vonoprazan	treatment	3	completed
NCT04613895	Treatment Effect According to Timing of Administration of DWP14012 40 mg	Abeprazan	treatment	Not Available	unknown_status
NCT02873702	Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis	Dexlansoprazole Lansoprazole	treatment	3	terminated
NCT05443984	JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis	Esomeprazole	treatment	3	completed
NCT01452698	Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis	Lansoprazole Vonoprazan	treatment	3	completed
NCT05050188	A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008	Lansoprazole	treatment	1	completed
NCT01642615	Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents	Dexlansoprazole	treatment	2	completed
NCT01306799	To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use	No drug interventions	Not Available	Not Available	completed
NCT04888819	Treatment Effect According to Timing of Administration of DWP14012 40 mg	Abeprazan	treatment	Not Available	unknown_status
NCT02388724	Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis	Lansoprazole Vonoprazan	treatment	3	completed
NCT02096458	Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets	Dexlansoprazole	treatment	1	completed
NCT01874535	Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy	Esomeprazole	treatment	4	completed
NCT00586963	Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis	No drug interventions	Not Available	Not Available	completed
NCT02995239	A Study to Compare the Pharmacokinetic Characteristics of CJ-12420	Tegoprazan	treatment	1	completed
NCT01865825	Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?	No drug interventions	Not Available	Not Available	completed
NCT04124926	Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis	Lansoprazole Vonoprazan	treatment	3	completed
NCT03006874	Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis	Esomeprazole Tegoprazan	treatment	3	completed
NCT00228527	Esomeprazole for Treatment of GERD in Pediatric Patients	Esomeprazole	treatment	4	completed
NCT00206180	NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis	Esomeprazole	Not Available	4	completed
NCT01459367	Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis	Lansoprazole Vonoprazan	treatment	3	completed
NCT03736369	Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)	Abeprazan Esomeprazole	treatment	3	completed
NCT02679508	Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety	Lansoprazole Vonoprazan	treatment	4	completed